2021 Fiscal Year Annual Research Report
Role of the angiocrine factor Egfl7 in multiple myeloma progression and drug resistance
| Project/Area Number |
19K08857
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
ハイジッヒ ベアーテ 順天堂大学, 大学院医学研究科, 特任准教授 (30372931)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
服部 浩一 順天堂大学, 大学院医学研究科, 特任先任准教授 (10360116)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | myltiple myeloma |
|---|
| Outline of Annual Research Achievements |
This year, we showed that anti-EGFL7 antibody treatment of human multiple myeloma cells prevented myeloma cell growth in vivo. In addition, we showed that multiple myeloma cell lines showed upregulation of the angiocrine factor EGFL7 and its receptors, beta3 integrin after bortezomib especially when developing drug resistance. Combined treatment of bortezomib with anti-EGFL7 or drugs targeting beta3 integrin could effectively control growth in murine and human multiple myeloma cells. Our studies indicate that cotreatment of conventional anti-myeloma drugs and drugs targeting either EGFL7 or beta3 integrin show the best anti-myeloma effects. These data confirmed and extended our data published in the previous years on the impact of EGFL7. We published the following manuscripts in 2021: Heissig et al. Cancers, 1014, 2021; Heissig et al. Intern. J of Molecular Sciences., 2021; Salama et al. Int J Mol Sci. Jul 29;22(15):8151,2021).
|
| Remarks |
none.
|
